Erlotinib was first approved more than a decade ago for the treatment of patients with advanced non-small cell lung cancer (NSCLC), following failure on at least 1 prior chemotherapy treatment.

Loss of heterozygosity predicted increased risk for oral cancer among patients with oral premalignant lesions, according to the results of a randomized clinical trial.Although loss of ...

Another study showed greater than 20% 6-month progression-free survival (PFS) in recurrent GBM after erlotinib treatment. 11 Another study noted erlotinib activity in particular in GBM with combined ...

Erlotinib demonstrated good clinical benefit with acceptable toxicity for the treatment of women with vulvar carcinoma, according to findings from a phase-2 trial.

One-hundred fifteen patients were enrolled onto this study. Forty-seven percent of patients received erlotinib at 150 mg daily throughout the entire study, 6% had dose escalations, and 46% required ...

The FDA has approved the first ever blood-based companion diagnostic test. The cobas EGFR Mutation Test v2 was developed by Roche for the drug erlotinib (Tarceva), which was developed by Astellas ...

Erlotinib and gefitinib are tyrosine kinase inhibitors that target the EGFR by binding competitively to the ATP-binding pocket of the intracellular kinase domain. 1, 2 Two initial studies in ...

We used erlotinib-resistant A549 lung adenocarcinoma cells for initial characterisation of the role of mir-200c in erlotinib sensitivity and EMT induction.

Erlotinib maintenance therapy significantly improves progression-free survival and overall survival in patients with advanced nonsmall-cell lung cancer (NSCLC).

The cost of adding erlotinib to the treatment of patients with nonsmall cell lung cancer (NSCLC) is about $95,000 per life-year gained. But it is a much better value in certain patients.

Erlotinib is recommended as an option for treating locally advanced or metastatic non‑small‑cell lung cancer that has progressed in people who have had non‑targeted chemotherapy because of delayed ...

Therefore, erlotinib was again discontinued, and we administered 125 mg of aprepitant on day 1 after discontinuation and 80 mg of aprepitant on days 2 and 3, with the aim of treating the pruritus.